Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Mithra Pharmaceuticals BRU:MITRA.BL, BE0974283153

  • 0,222 23 apr 2024 12:05
  • 0,000 (0,00%) Dagrange 0,221 - 0,230
  • 33.571 Gem. (3M) 382,3K

Mithra in 2022 - het jaar van beLEONing?!

3.656 Posts
Pagina: «« 1 ... 114 115 116 117 118 ... 183 »» | Laatste | Omlaag ↓
  1. Donatello 8 september 2022 11:12
    Mayne Pharma. Ik verwacht ook geen faillissement, men is bijna terug op track om positief te draaien, na al hun veranderingen. Vanaf 2025 terug positief is het vooruitzicht, het is wel zo dat de schulden nog stijgen tot die tijd, maar men heeft nog altijd meer geld dan schulden. Ik verwacht ook niet dat ze zullen moeten lenen om die periode door te komen. Ze hebben nog 557miljoen eigen vermogen. Schuld is 367 miljoen en blijft al enkele jaren stabiel.
  2. forum rang 10 DeZwarteRidder 12 september 2022 08:13
    The obscure US financier backing the ASX’s hot stocks

    LDA Capital is the go-to financier for a handful of speculative ASX plays, and its model is now being embraced by local funds.
    Jonathan ShapiroSenior reporter
    Aug 4, 2022 – 11.26am

    What do you do if you’re a small listed company with big ambitions to finance but only small investors backing your vision? One solution is to call Los Angeles investment firm LDA Capital.

    No matter how small, speculative or even tarnished a prospect might be, LDA Capital appears willing to provide a healthily sized equity financing package that can be tapped in all market conditions.

    Arrangements that allow small companies to raise new capital on the back of retail enthusiasm are not without risks. Louise Kennerley

    The little known LDA Capital was founded in 2018 according to its website that lists former investment banker Anthony Romano and Warren Baker as its leaders.

    While it invests extensively around the world in public and private companies, LDA has found a happy hunting ground at the speculative end of the Australian sharemarket.

    It has been involved in financing some of the ASX’s most divisive companies including Brainchip, Skin Element and GetSwift – which, having defected to Canada, has this week filed for administration.

    LDA Capital’s financing model is intriguing and, while it does appear well suited to speculative growth companies that need capital but lack institutional support, it’s not without risks.

    The way a typical LDA financing arrangement works is as follows: LDA will agree to provide a set amount of equity financing to a company – say a minimum of $10 million and a maximum of $50 million, over a certain period. The company, at its discretion, can issue periodic capital calls that draw on the funding.

    When a call is made, a certain number of shares are issued to LDA Capital, which then sells them into the open market over, say, 10 days.

    The number of shares issued to LDA is limited by the average turnover of the stock to avoid it being stuck with more shares than the market can absorb.

    LDA does not pay for the shares upfront, only on settlement. The price it pays for the shares (that is, the amount of new capital raised) is based on the volume weighted average price only after the call is made, less a discount of about 10 per cent.


    It’s an arrangement that appears well suited to small companies that have drummed up solid retail interest through penny stock websites and sharemarket forums, yet haven’t been embraced by the big end of town.

    LDA Capital’s most high-profile Australian play certainly fits that brief: Brainchip, which has surged up the market cap ranks and was newly admitted into the S&P/ASX 200.
    Brain explosion

    Brainchip has had financing arrangements in place with LDA since August 2020 in which it could call on a minimum of $20 million of financing and a maximum of $45 million of capital over a one-year period. LDA was also paid fees and granted over 100 million options, netting tens of millions of dollars of profit.

    en.wikipedia.org/wiki/Death_spiral_fi...
  3. Brahim_av 12 september 2022 10:48
    quote:

    DeZwarteRidder schreef op 12 september 2022 08:13:

    The obscure US financier backing the ASX’s hot stocks

    LDA Capital is the go-to financier for a handful of speculative ASX plays, and its model is now being embraced by local funds.
    Jonathan ShapiroSenior reporter
    Aug 4, 2022 – 11.26am

    What do you do if you’re a small listed company with big ambitions to finance but only small investors backing your vision? One solution is to call Los Angeles investment firm LDA Capital.

    No matter how small, speculative or even tarnished a prospect might be, LDA Capital appears willing to provide a healthily sized equity financing package that can be tapped in all market conditions.

    Arrangements that allow small companies to raise new capital on the back of retail enthusiasm are not without risks. Louise Kennerley

    The little known LDA Capital was founded in 2018 according to its website that lists former investment banker Anthony Romano and Warren Baker as its leaders.

    While it invests extensively around the world in public and private companies, LDA has found a happy hunting ground at the speculative end of the Australian sharemarket.

    It has been involved in financing some of the ASX’s most divisive companies including Brainchip, Skin Element and GetSwift – which, having defected to Canada, has this week filed for administration.

    LDA Capital’s financing model is intriguing and, while it does appear well suited to speculative growth companies that need capital but lack institutional support, it’s not without risks.

    The way a typical LDA financing arrangement works is as follows: LDA will agree to provide a set amount of equity financing to a company – say a minimum of $10 million and a maximum of $50 million, over a certain period. The company, at its discretion, can issue periodic capital calls that draw on the funding.

    When a call is made, a certain number of shares are issued to LDA Capital, which then sells them into the open market over, say, 10 days.

    The number of shares issued to LDA is limited by the average turnover of the stock to avoid it being stuck with more shares than the market can absorb.

    LDA does not pay for the shares upfront, only on settlement. The price it pays for the shares (that is, the amount of new capital raised) is based on the volume weighted average price only after the call is made, less a discount of about 10 per cent.


    It’s an arrangement that appears well suited to small companies that have drummed up solid retail interest through penny stock websites and sharemarket forums, yet haven’t been embraced by the big end of town.

    LDA Capital’s most high-profile Australian play certainly fits that brief: Brainchip, which has surged up the market cap ranks and was newly admitted into the S&P/ASX 200.
    Brain explosion

    Brainchip has had financing arrangements in place with LDA since August 2020 in which it could call on a minimum of $20 million of financing and a maximum of $45 million of capital over a one-year period. LDA was also paid fees and granted over 100 million options, netting tens of millions of dollars of profit.

    en.wikipedia.org/wiki/Death_spiral_fi...
    Je hebt een punt hier, ik ben ook niet te vinden voor zulke wurgende financieringsconstructies.
    Gelukkig is hier op een bepaald moment een einde aan gekomen aan de LDA deal en is men andere vormen van financiering gaan zoeken.
    Ik denk dat het ergste voor Mithra achter de rug is (verwatering, financiering, imago). De koers zakt niet meer sterk (na de KV) en obligatielening van HB&WH.
    De focus ligt nu op Donesta veiligheidsstudie die wellicht mid oktober zal bekend worden gemaakt.
    De effectiviteit van Donesta in fase 3 was na 12 weken behandeling met E4 al gerapporteerd begin dit jaar.
    We krijgen binnenkort te horen of de effectiviteit tot 52 weken standhoudt. En of er geen AE's zijn.
    Als hier geen verassingen uitkomen, denk ik dat er kort daarna meer info naar buiten komt ivm nakende deal (Partner Donesta).
    Dit is een potentiëel keerpunt voor Mithra op weg naar success (of niet).
    Als echter blijkt dat de studieresultaten geen groot succes zijn, dan komt volgens mij de koers terug onder meer druk te staan.
  4. forum rang 10 DeZwarteRidder 12 september 2022 10:57
    quote:

    Brahim_av schreef op 12 september 2022 10:48:

    [...]Je hebt een punt hier, ik ben ook niet te vinden voor zulke wurgende financieringsconstructies.
    Gelukkig is hier op een bepaald moment een einde aan gekomen aan de LDA deal en is men andere vormen van financiering gaan zoeken.
    Ik denk dat het ergste voor Mithra achter de rug is (verwatering, financiering, imago). De koers zakt niet meer sterk (na de KV) en obligatielening van HB&WH.
    De focus ligt nu op Donesta veiligheidsstudie die wellicht mid oktober zal bekend worden gemaakt.
    De effectiviteit van Donesta in fase 3 was na 12 weken behandeling met E4 al gerapporteerd begin dit jaar.
    We krijgen binnenkort te horen of de effectiviteit tot 52 weken standhoudt. En of er geen AE's zijn.
    Als hier geen verassingen uitkomen, denk ik dat er kort daarna meer info naar buiten komt ivm nakende deal (Partner Donesta).
    Dit is een potentiëel keerpunt voor Mithra op weg naar success (of niet).
    Als echter blijkt dat de studieresultaten geen groot succes zijn, dan komt volgens mij de koers terug onder meer druk te staan.
    Je maakt een grote vergissing; het ergste moet nog komen.
  5. forum rang 10 DeZwarteRidder 12 september 2022 11:36
    Death spiral financing
    From Wikipedia, the free encyclopedia

    Death spiral financing is the result of a badly structured convertible financing used to fund primarily small cap companies in the marketplace, causing the company's stock to fall dramatically, which can lead to the company's ultimate downfall.

    Some small companies rely on selling convertible debt to large private investors (see private investment in public equity) to fund their operations and growth. This convertible debt, often convertible preferred stock or convertible debentures, can be converted to the common stock of the issuing company at a discount to the market value of the common stock at the time of each conversion.

    Under a “death spiral” scenario, the holder of the convertible debt might short the issuer's common stock at which time the debt holder converts some of the convertible debt to common shares with which he then covers the debt holder's short position. The debt holder continues to sell short and cover with converted stock, which, along with selling by other shareholders alarmed by the falling price, continually weakens the share price, making the shares unattractive to new investors and possibly severely limiting the company's ability to obtain new financing if necessary.

    The lender would have a potentially greater gain if the shares were to increase in value, but if they decrease in value, there is some protection. Otherwise, they would probably not be willing to lend the money because of the poor risk profiles of the companies interested in this type of financing.

    There are some ways to limit the "spiral" situation, e.g. by prohibiting short selling so as to have a stronger incentive for the debt holder to see the stock price increase. It is also worth noting that in a spiral scenario, it becomes more and more difficult for the debt holder to recover its investment because of the increasing volume of common stock it receives upon each conversion of its debt. Another mean to limit the "spiral" risk is to ensure that the amount of funding is in line with the trading activity of the common stock so as to reduce the potential decrease resulting from the sale of common stock by the debt holder.

    Companies willing to agree to financing on these terms often could not obtain funding through any other means due to their early development stage or credit risk profile. The terms, though viewed by some as onerous, give the lender a potential way to recover their debt regardless of what happens to the shares of the company, and the company an easy access to dilutive but relatively cheap funding in terms of cash cost.
3.656 Posts
Pagina: «« 1 ... 114 115 116 117 118 ... 183 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Mithra laat aandeelhouders schrikken

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links